Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kezar Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kezar Life Sciences's regulatory disclosures and financial reporting.
Kezar Life Sciences director John Franklin Fowler received a stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation grant. The vesting schedule indicates a one-year cliff vesting period, which aligns with typical board member equity compensation structures. The 10-year exercise window from grant date is also standard practice for director stock options.
Kezar Life Sciences (Nasdaq: KZR) filed a Form 8-K disclosing the voting results of its 17 June 2025 annual meeting (Item 5.07).
Shareholders elected three Class I directors to serve until the 2028 meeting: Elizabeth Garner, M.D. (2,148,505 for / 1,793,162 withheld), Michael Kauffman, M.D., Ph.D. (1,618,735 for / 2,322,932 withheld) and Courtney Wallace (1,551,353 for / 2,390,314 withheld).
The meeting also approved, on an advisory basis, executive compensation (2,151,745 for; 1,781,942 against; 7,980 abstain) and ratified KPMG LLP as independent auditor for fiscal 2025 (6,116,820 for; 56,801 against; 8,526 abstain).
No financial performance updates, strategic announcements or other material events were included.